Standout Papers

Extending Aromatase-Inhib... 2016 2026 2019 2022 2016 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation benchmark for papers published in the same subfield and year, or reaches the top citation threshold in at least one of its specific research topics.

  1. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
    2016 411 citations Paul E. Goss, James N. Ingle et al. New England Journal of Medicine profile →

Immediate Impact

2 by Nobel laureates 9 from Science/Nature 54 hit
Sub-graph 1 of 21

Citing Papers

Screening for Breast Cancer
2024 Hit
Fluorescent Probes for Disease Diagnosis
2024 Hit
2 intermediate papers

Works of S. Rubin being referenced

A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.
2016
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
2016 Hit

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
S. Rubin 560 303 268 248 225 20 957
Reginald P. Pugh 582 1.0× 221 0.7× 217 0.8× 270 1.1× 171 0.8× 34 1.1k
Naseem J. Zojwalla 403 0.7× 481 1.6× 428 1.6× 274 1.1× 153 0.7× 25 946
J J Costanzi 642 1.1× 272 0.9× 295 1.1× 284 1.1× 187 0.8× 36 1.2k
Rosemary Young 693 1.2× 193 0.6× 226 0.8× 198 0.8× 241 1.1× 15 1.0k
Rangaswamy Govindarajan 430 0.8× 189 0.6× 428 1.6× 130 0.5× 171 0.8× 39 973
Rubina Qamar 477 0.9× 204 0.7× 197 0.7× 232 0.9× 68 0.3× 21 889
W.R. Bezwoda 366 0.7× 196 0.6× 203 0.8× 95 0.4× 177 0.8× 41 891
Margaret A. Tucker 382 0.7× 134 0.4× 379 1.4× 199 0.8× 87 0.4× 15 1.2k
William Dahut 323 0.6× 190 0.6× 465 1.7× 287 1.2× 120 0.5× 19 888
M Hunt 589 1.1× 157 0.5× 106 0.4× 268 1.1× 408 1.8× 21 999

All Works

Loading papers...

Rankless by CCL
2026